1. N-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1h-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide
2. Surufatinib
1. 1308672-74-3
2. Surufatinib
3. N-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1h-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide
4. Hmpl-012
5. Kdr-in-1
6. 1816307-67-1
7. Hmpl012
8. Surufatinib [inn]
9. Surufatinib [usan]
10. B2k5l1l8s9
11. N-[2-(dimethylamino)ethyl]-1-[3-[[4-[(2-methyl-1h-indol-5-yl)oxy]pyrimidin-2-yl]amino]phenyl]methanesulfonamide
12. Benzenemethanesulfonamide, N-(2-(dimethylamino)ethyl)-3-((4-((2-methyl-1h-indol-5-yl)oxy)-2-pyrimidinyl)amino)-
13. Benzenemethanesulfonamide, N-[2-(dimethylamino)ethyl]-3-[[4-[(2-methyl-1h-indol-5-yl)oxy]-2-pyrimidinyl]amino]-
14. Sulanda
15. N-[2-(dimethylamino)ethyl]-1-[3-({4-[(2-methyl-1h-indol-5-yl)oxy]pyrimidin-2-yl}amino)phenyl]methanesulfonamide
16. Sulfatinib [who-dd]
17. Sulfatinib; Hmpl-012
18. Unii-b2k5l1l8s9
19. Surufatinib [who-dd]
20. Gtpl9769
21. Schembl1822601
22. Chembl4297190
23. Bcp14757
24. Ex-a2524
25. Nsc797937
26. Who 10349
27. Akos030632837
28. Zinc117218067
29. Cs-5949
30. Db15106
31. Nsc-797937
32. Ac-35852
33. As-74954
34. Hmpl-012;hmpl 012;hmpl012
35. Hy-12297
36. Vegfr2 Inhibitor [wo2011060746]
37. D71057
38. A926546
39. N-(2-(dimethylamino) Ethyl)-1-(3-((4-((2-methyl-1h-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide
40. N-(2-(dimethylamino) Ethyl)-1-(3-((4-(2-methyl-1h-indol-5-yloxy) Pyrimidin-2-yl) Amino) Phenyl) Methanesulfonamide
Molecular Weight | 480.6 g/mol |
---|---|
Molecular Formula | C24H28N6O3S |
XLogP3 | 3.4 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 10 |
Exact Mass | 480.19435995 g/mol |
Monoisotopic Mass | 480.19435995 g/mol |
Topological Polar Surface Area | 121 Ų |
Heavy Atom Count | 34 |
Formal Charge | 0 |
Complexity | 733 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms), Treatment of malignant neoplasms of haematopoietic and lymphoid tissue
LOOKING FOR A SUPPLIER?